Agents that prevent clotting.
DrugDrug NameDrug Indication
DB00001LepirudinFor the treatment of heparin-induced thrombocytopenia
DB00006BivalirudinFor treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
DB00054AbciximabAbciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
DB00102BecaplerminFor topical treatment of skin ulcers (from diabetes)
DB00266DicoumarolFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
DB00278ArgatrobanArgatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
DB00407ArdeparinFor prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
DB00498PhenindioneFor the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili. Also used for anticoagulant prophylaxis.
DB00569Fondaparinux sodiumApproved for: (1) prophylaxis of VTE for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement and knee surgery; (2) prophylaxis of VTE patients undergoing abdominal surgery who are at high risk of thromboembolic complications (e.g. patients undergoing abdominal cancer surgery); (3) treatment of acute DVT and PE; (4) management of UA and NSTEMI for the prevention of death and subsequent myocardial infarction (MI); and (5) management of STEMI for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy. Fondaparinux should not be used as the sole anticoagulant during percutaneous coronary intervention (PCI) due to an increased risk of guiding catheter thrombosis.
DB00682WarfarinFor the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.
DB00686Pentosan PolysulfateFor the relief of bladder pain or discomfort associated with interstitial cystitis.
DB00946PhenprocoumonUsed for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).
DB00974Edetic AcidFor the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
DB01109HeparinUnfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.
DB01225EnoxaparinFor the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
DB01418AcenocoumarolFor the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.
DB04272Citric AcidNot Available
DB04898XimelagatranFor the treatment of acute deep vein thrombosis.
DB05099AncrodFor the treatment of established deep vein thrombosis; central retinal and branch vein thrombosis; priapism; pulmonary hypertension of embolic origin; embolism after insertion of prosthetic cardiac valves; rethrombosis after thrombolytic therapy and rethrombosis after vascular surgery. It is also indicated for the prevention of deep venous thrombosis after repair of the fractured neck of a femur.
DB06154Pentaerythritol TetranitrateNot Available
DB06228RivaroxabanRivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).
DB06271SulodexideSulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated in the treatment of diabetic kidney disease and diabetic neuropathy. New anti-inflammatory properties have also extended its use in venous disease.
DB06406IdraparinuxInvestigated for use/treatment in thrombosis, venous thromboembolism, strokes, heart disease, and atrial fibrillation.
DB06605ApixabanApixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
DB06635OtamixabanInvestigated for use/treatment in thrombosis.
DB06695Dabigatran etexilateDabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves.
DB06754DanaparoidNot Available
DB06779DalteparinDalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes). It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
DB07767Ferulic acidNot Available
DB08794Ethyl biscoumacetateNot Available
DB08813NadroparinNadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction
DB09075EdoxabanEdoxaban is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
DB09255DextranFor use as an antithrombotic (antiplatelet), to reduce blood viscosity, and as a volume expander in hypovolaemia.
DB09259ReviparinUsed in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
DB09261CertoparinUsed in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
DB11076Dextran 70Not Available
DB11095DesirudinIndicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
DB11122Dextran 40Dextran 40 is indicated for use in the adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery or other trauma. Also, indicated for use as a priming fluid, either as a sole prime or as an additive, in pump oxygenators during extracorporeal circulation. Dextran 40 is also indicated for use in prophylaxis of venous thrombosis and pulmonary embolism in patients undergoing procedures known to be associated with a high incidence of thromboembolic complications, such as hip surgery.
DB11241Dextran 75Not Available
DB11268ProtocatechualdehydeNot Available
DB11312Protein CProtein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
DB11598Antithrombin III humanAntithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism
DB11728FondaparinuxNot Available
DB11984LetaxabanNot Available
DB12289DarexabanNot Available
DB12598NafamostatUsed as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation.
DB12831GabexateNo approved indication.
DB13124TroxerutinNot Available
DB13136FluindioneNot Available
DB13149Protein S humanFor use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy [FDA Label]. Protein S is administered as part of a cocktail containing several other coagulation factors.
DrugDrug NameTargetType
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00102BecaplerminPlatelet-derived growth factor receptor betatarget
DB00102BecaplerminPlatelet-derived growth factor receptor alphatarget
DB00266DicoumarolVitamin K epoxide reductase complex subunit 1target
DB00266DicoumarolNAD(P)H dehydrogenase [quinone] 1target
DB00266DicoumarolQuinone oxidoreductasetarget
DB00266DicoumarolCytochrome P450 2C9enzyme
DB00266DicoumarolSerum albumincarrier
DB00278ArgatrobanCytochrome P450 3A4enzyme
DB00278ArgatrobanCytochrome P450 3A5enzyme
DB00407ArdeparinHeparin cofactor 2target
DB00498PhenindioneVitamin K epoxide reductase complex subunit 1target
DB00569Fondaparinux sodiumAntithrombin-IIItarget
DB00569Fondaparinux sodiumCoagulation factor Xtarget
DB00682WarfarinVitamin K epoxide reductase complex subunit 1target
DB00682WarfarinCytochrome P450 2C8enzyme
DB00682WarfarinCytochrome P450 1A2enzyme
DB00682WarfarinCytochrome P450 2C9enzyme
DB00682WarfarinAlpha-1-acid glycoprotein 1carrier
DB00682WarfarinSerum albumincarrier
DB00682WarfarinCytochrome P450 1A1enzyme
DB00682WarfarinCytochrome P450 2C19enzyme
DB00682WarfarinCytochrome P450 3A4enzyme
DB00682WarfarinCytochrome P450 2C18enzyme
DB00682WarfarinNuclear receptor subfamily 1 group I member 2target
DB00686Pentosan PolysulfateFibroblast growth factor 1target
DB00686Pentosan PolysulfateFibroblast growth factor 4target
DB00686Pentosan PolysulfateFibroblast growth factor 2target
DB00946PhenprocoumonVitamin K epoxide reductase complex subunit 1target
DB00946PhenprocoumonAlpha-1-acid glycoprotein 1carrier
DB00946PhenprocoumonSerum albumincarrier
DB00946PhenprocoumonCytochrome P450 2C9enzyme
DB00946PhenprocoumonCytochrome P450 3A4enzyme
DB00946PhenprocoumonCytochrome P450 2C8enzyme
DB00974Edetic AcidLeadtarget
DB00974Edetic AcidIrontarget
DB00974Edetic AcidManganese cationtarget
DB00974Edetic AcidAdenosine deaminaseenzyme
DB00974Edetic AcidCytochrome P450 1A2enzyme
DB00974Edetic AcidSerum paraoxonase/lactonase 3enzyme
DB00974Edetic AcidCytochrome P450 19A1enzyme
DB01109HeparinCoagulation factor Xtarget
DB01109HeparinFibroblast growth factor receptor 4target
DB01109HeparinFibroblast growth factor 4target
DB01109HeparinFibroblast growth factor 19target
DB01109HeparinFibroblast growth factor receptor 1target
DB01109HeparinFibroblast growth factor 1target
DB01109HeparinFibroblast growth factor receptor 2target
DB01109HeparinFibroblast growth factor 2target
DB01109HeparinPlatelet factor 4target
DB01109HeparinHepatocyte growth factortarget
DB01225EnoxaparinCoagulation factor Xtarget
DB01418AcenocoumarolVitamin K epoxide reductase complex subunit 1target
DB01418AcenocoumarolCytochrome P450 2C9enzyme
DB01418AcenocoumarolCytochrome P450 1A2enzyme
DB01418AcenocoumarolSerum albumincarrier
DB01418AcenocoumarolAlpha-1-acid glycoprotein 1carrier
DB01418AcenocoumarolCytochrome P450 2C19enzyme
DB01418AcenocoumarolCytochrome P450 3A4enzyme
DB04272Citric AcidCell division protein FtsZtarget
DB04272Citric AcidAngiogenintarget
DB04272Citric AcidBeta-lactamase 2target
DB04272Citric AcidUridine-cytidine kinase 2target
DB04272Citric AcidTumor necrosis factor ligand superfamily member 13Btarget
DB04272Citric AcidBetaine--homocysteine S-methyltransferase 1target
DB04272Citric AcidTryptophan--tRNA ligasetarget
DB04272Citric AcidAldose reductasetarget
DB04272Citric AcidCitrate synthase, mitochondrialtarget
DB04272Citric AcidHeparan sulfate glucosamine 3-O-sulfotransferase 3A1target
DB04272Citric AcidcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB04272Citric AcidProto-oncogene tyrosine-protein kinase Srctarget
DB04272Citric AcidRibonuclease pancreatictarget
DB04272Citric AcidIsocitrate dehydrogenase [NADP]target
DB04272Citric AcidGlycine N-methyltransferasetarget
DB04272Citric AcidEosinophil cationic proteintarget
DB04272Citric AcidBeta-lactamasetarget
DB04272Citric AcidMolybdenum cofactor guanylyltransferasetarget
DB04272Citric AcidFumarate hydratase class IItarget
DB04272Citric Acid6-phosphogluconolactonasetarget
DB04272Citric AcidOxygen-insensitive NAD(P)H nitroreductasetarget
DB04272Citric AcidGag-Pro-Pol polyproteintarget
DB04272Citric AcidL-amino-acid oxidasetarget
DB04272Citric AcidMacrophage migration inhibitory factortarget
DB04272Citric AcidCarboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1target
DB04272Citric Acid1-deoxy-D-xylulose 5-phosphate reductoisomerasetarget
DB04272Citric AcidTryptophan synthase alpha chaintarget
DB04272Citric AcidSialidasetarget
DB04272Citric AcidKHG/KDPG aldolasetarget
DB04272Citric AcidCytochrome c peroxidasetarget
DB04272Citric AcidHepatocyte growth factor-regulated tyrosine kinase substratetarget
DB04272Citric AcidInvasintarget
DB04272Citric AcidIntron-associated endonuclease 1target
DB04272Citric AcidShort tail fiber proteintarget
DB04272Citric AcidMalate dehydrogenase, mitochondrialtarget
DB04272Citric AcidN5-carboxyaminoimidazole ribonucleotide mutasetarget
DB04272Citric Acid50S ribosomal protein L4target
DB04272Citric AcidCarboxypeptidase Btarget
DB04272Citric AcidHexon proteintarget
DB04272Citric AcidRiboflavin biosynthesis protein RibFtarget
DB04272Citric AcidBeta-fructosidasetarget
DB04272Citric AcidPutative stringent starvation protein Atarget
DB04272Citric AcidCitrate synthasetarget
DB04272Citric AcidRNA 3'-terminal phosphate cyclasetarget
DB04272Citric AcidU6 snRNA-associated Sm-like protein LSm6target
DB04272Citric AcidPleckstrin homology domain-containing family A member 1target
DB04272Citric AcidFe(3+)-binding periplasmic proteintarget
DB04272Citric AcidSignal recognition particle receptor FtsYtarget
DB04272Citric AcidNicotinate-nucleotide adenylyltransferasetarget
DB04272Citric AcidN utilization substance protein B homologtarget
DB04272Citric AcidComplement component C8 gamma chaintarget
DB04272Citric AcidRibonucleoside-diphosphate reductase subunit betatarget
DB04272Citric AcidGlutamine synthetase 1target
DB04272Citric AcidCitrate synthasetarget
DB04272Citric AcidProstaglandin F synthasetarget
DB04272Citric AcidAdenine phosphoribosyltransferasetarget
DB04272Citric AcidGlucose-1-phosphate thymidylyltransferasetarget
DB04272Citric AcidGlyoxalase family proteintarget
DB04272Citric AcidLaccase domain protein YfiHtarget
DB04272Citric AcidRibose-5-phosphate isomerase Atarget
DB04272Citric AcidGMP synthase [glutamine-hydrolyzing]target
DB04272Citric AcidInosine triphosphate pyrophosphatasetarget
DB04272Citric AcidLysozymetarget
DB04272Citric AcidGlycerol uptake operon antiterminator regulatory proteintarget
DB04272Citric Acid3-carboxy-cis,cis-muconate cycloisomerasetarget
DB04272Citric AcidPyruvate decarboxylasetarget
DB04272Citric AcidSolute carrier organic anion transporter family member 2B1transporter
DB04898XimelagatranCytochrome P450 2C9enzyme
DB05099AncrodFibrinogen alpha chaintarget
DB06228RivaroxabanCoagulation factor Xtarget
DB06228RivaroxabanCytochrome P450 3A4enzyme
DB06228RivaroxabanCytochrome P450 2J2enzyme
DB06228RivaroxabanMultidrug resistance protein 1transporter
DB06228RivaroxabanCytochrome P450 3A5enzyme
DB06271SulodexideHeparin cofactor 2target
DB06406IdraparinuxCoagulation factor Xtarget
DB06605ApixabanCoagulation factor Xtarget
DB06605ApixabanCytochrome P450 3A4enzyme
DB06605ApixabanCytochrome P450 1A2enzyme
DB06605ApixabanCytochrome P450 2C8enzyme
DB06605ApixabanCytochrome P450 2C9enzyme
DB06605ApixabanCytochrome P450 2C19enzyme
DB06605ApixabanCytochrome P450 2J2enzyme
DB06605ApixabanMultidrug resistance protein 1transporter
DB06605ApixabanATP-binding cassette sub-family G member 2transporter
DB06605ApixabanCytochrome P450 3A5enzyme
DB06635OtamixabanCoagulation factor Xtarget
DB06695Dabigatran etexilateProthrombintarget
DB06695Dabigatran etexilateMultidrug resistance protein 1transporter
DB06695Dabigatran etexilateLiver carboxylesterase 1enzyme
DB06695Dabigatran etexilateCocaine esteraseenzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 1-9enzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 2B7enzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 2B15enzyme
DB06695Dabigatran etexilateRibosyldihydronicotinamide dehydrogenase [quinone]enzyme
DB06779DalteparinVascular endothelial growth factor Atarget
DB06779DalteparinTissue factor pathway inhibitortarget
DB07767Ferulic acidEndo-1,4-beta-xylanase Ytarget
DB07767Ferulic acidEndo-1,4-beta-xylanase Ztarget
DB07767Ferulic acidEst1etarget
DB07767Ferulic acidO-methyltransferasetarget
DB08794Ethyl biscoumacetateGlutamine synthetaseenzyme
DB08813NadroparinProto-oncogene c-Fostarget
DB08813NadroparinMyc proto-oncogene proteintarget
DB09075EdoxabanCoagulation factor Xtarget
DB09075EdoxabanMultidrug resistance protein 1transporter
DB11095DesirudinCarboxypeptidase A1enzyme
DB11598Antithrombin III humanAntithrombin-IIItarget
DB12598NafamostatIntercellular adhesion molecule 1target
DB12598NafamostatCoagulation factor Xtarget
DB12598NafamostatCoagulation factor XIItarget
DB12598NafamostatSolute carrier family 22 member 1transporter
DB12598NafamostatSolute carrier family 22 member 2transporter
DB12831GabexateComplement C1s subcomponentenzyme
DB12831GabexateComplement C1r subcomponentenzyme
DB12831GabexatePlasma kallikreintarget
DB13149Protein S humanCoagulation factor Vtarget
DB13149Protein S humanCoagulation factor Xtarget
DB13149Protein S humanVitamin K-dependent protein Ctarget